Yusuke Echigoya

List of Publications by Year
in descending order

32	1,039	393982	454577
papers	citations	19 h-index	30 g-index

32	32	32	937
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	21
2	DUX4 Transcript Knockdown with Antisense 2â€²-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy. Molecular Therapy, 2021, 29, 848-858.	3.7	24
3	A fatal case of a captive snowy owl (Bubo scandiacus) with Haemoproteus infection in Japan. Parasitology Research, 2021, 120, 277-288.	0.6	13
4	A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. International Journal of Molecular Sciences, 2021, 22, 13065.	1.8	9
5	Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16509-16515.	3.3	40
6	Exons 45â€“55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. Molecular Therapy, 2019, 27, 2005-2017.	3.7	35
7	Amelioration of intracellular Ca2+ regulation by exon-45 skipping in Duchenne muscular dystrophy-induced pluripotent stem cell-derived cardiomyocytes. Biochemical and Biophysical Research Communications, 2019, 520, 179-185.	1.0	14
8	Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates. Molecular Therapy, 2019, 27, 76-86.	3.7	24
9	Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges. Journal of Personalized Medicine, 2018, 8, 41.	1.1	61
10	Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS ONE, 2018, 13, e0197084.	1.1	22
11	Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy. Methods in Molecular Biology, 2017, 1565, 201-213.	0.4	19
12	Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4213-4218.	3.3	94
13	Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. Journal of Human Genetics, 2017, 62, 459-463.	1.1	53
14	Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular Therapy, 2017, 25, 2561-2572.	3.7	63
15	LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of theÂSMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Scientific Reports, 2017, 7, 3672.	1.6	42
16	Dystrophin-deficient cardiomyocyte derived from Duchenne Muscular Dystrophy specific induced pluripotent stem cells carrying the deletion of exon 46-55 in DMD gene. Journal of the Neurological Sciences, 2017, 381, 859.	0.3	0
17	Current Translational Research and Murine Models For Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2016, 3, 29-48.	1.1	43
18	Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background. Scientific Reports, 2016, 6, 38371.	1.6	47

#	Article	IF	Citations
19	623. Dystrophin Exon 52-Deleted Pigs as a New Animal Model of Duchenne Muscular Dystrophy: Its Characterization and Potential as a Tool for Developing Exon Skipping Therapy. Molecular Therapy, 2016, 24, S247.	3.7	0
20	Deletion of exons 3â^'9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. Journal of Human Genetics, 2016, 61, 663-667.	1.1	45
21	Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45â€“55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice. Molecular Therapy - Nucleic Acids, 2015, 4, e225.	2.3	67
22	In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy. PLoS ONE, 2015, 10, e0120058.	1.1	45
23	Dystrophin-deficient large animal models: translational research and exon skipping. American Journal of Translational Research (discontinued), 2015, 7, 1314-31.	0.0	38
24	Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides. Nucleic Acid Therapeutics, 2014, 24, 57-68.	2.0	55
25	Mutation Types and Aging Differently Affect Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice. PLoS ONE, 2013, 8, e69194.	1.1	26
26	Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?. Expert Opinion on Biological Therapy, 2012, 12, 1141-1152.	1.4	35
27	Effects of extracellular lactate on production of reactive oxygen species by equine polymorphonuclear leukocytes in vitro. American Journal of Veterinary Research, 2012, 73, 1290-1298.	0.3	10
28	Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs. Nucleic Acid Therapeutics, 2012, 22, 306-315.	2.0	69
29	Molecular cloning and expression of bottlenose dolphin CD34. Veterinary Immunology and Immunopathology, 2011, 139, 303-307.	0.5	5
30	Molecular characterization of glycogen synthase 1 and its tissue expression profile with type II hexokinase and muscle-type phosphofructokinase in horses. Molecular Biology Reports, 2011, 38, 461-469.	1.0	3
31	Molecular characterization and expression pattern of the equine lactate dehydrogenase A and B genes. Gene, 2009, 447, 40-50.	1.0	14
32	Molecular characterization and expression of the equine M1 and M2-pyruvate kinase gene. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2008, 151, 125-132.	0.7	3